Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003237 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach

A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase
55
Enrollment target

NCT00003237 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 55 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003237, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
55 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of paclitaxel and cisplatin, given after surgery in treating patients with cancer of the esophagus or stomach.

Interventions

  • DRUG cisplatin
  • DRUG paclitaxel
  • PROCEDURE surgical procedure

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 1998-06-22
Phase Phase 2

Sponsor

Eastern Cooperative Oncology Group

141 total trials

What the Registry Record Tells You About NCT00003237

The ClinicalTrials.gov registry entry for NCT00003237 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00003237 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003237 about?

NCT00003237 is a clinical study titled "Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting ...

What is the current status of trial NCT00003237?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 1998-06-22.

What interventions are being tested in trial NCT00003237?

The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), surgical procedure (PROCEDURE).

Who is sponsoring clinical trial NCT00003237?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.